GTC Biotherapeutics (fka GTCB)

[quantumdot]

re: FOB mAbs

could you please clarify? in the first sentence you imply there is some irrational fear (amongst generic companies) that GTCs mAbs may be different and thus require a full clinical trial pathway and then in the second sentence you say that indeed GTCs mAbs are different and have different activity.

in effect you are saying that the chance of GTCs technology being used for production of FOB is very very low?

is that not the opposite of the investment/business case that Dew makes for this company?